Skip to main content
. Author manuscript; available in PMC: 2015 Jan 22.
Published in final edited form as: Cochrane Database Syst Rev. 2009 Jan 21;(1):CD007324. doi: 10.1002/14651858.CD007324.pub2

Table 5.

Table 2: Randomized controlled trial on IVTA for CRVO-ME

Study # Eyes Intervention Control Follow up Key outcomes
Ramezani 2006 27 eyes 4 mg Natural history 4 months Compared to natural history, VA and central macular thickness of treated CRVO was significantly improved at 1 and 2 months respectively
No significant difference in occurrence of neovascularisation of iris in both groups

CRVO: central retinal vein occlusion

VA: visual acuity